Pharmaceutical company Neuraxpharm Group reported on Wednesday the formation of Neuraxpharm Portugal in Lisbon, expanding its operations in Southern Europe.
Neuraxpharm Portugal will be part of the company's Southern European Region that comprises Italy, Spain and now Portugal.
Through the new subsidiary, Neuraxpharm will leverage its industry networks and central nervous system (CNS) expertise to make its extensive portfolio available to patients. It is planning the first commercial launch in December this year with a probiotic product.
The company aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market.
Javier Mercadé, the general manager of Italy and Spain, was appointed as head of Southern Region earlier this year and Teng Dias has been named as commercial director of the Neuraxpharm Portugal business.
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
Bayer receives FDA approval for AMBELVIST MRI contrast agent
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Verge Labs and Tenacia Biotechnology collaborate on advancing Tenacia's CNS pipeline
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Solvonis Therapeutics secures second US patent for PTSD compound series
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
TheraCryf advances lead addiction programme to final preclinical stage
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research